An affiliate of the American Society of Clinical Oncology - Learn More

Open Trials

Breast Cancer Trials:

Previously treated metastatic HER2+Breast Cancer

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
New sub-study includes margetuximab plus chemotherapy with decreased infusion time.
For questions, please contact 480-398-7671.


Previously treated Hormone receptor-positive, HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC)
For questions, please contact 480-398-7671.

Colorectal Cancer Trials:

2nd line treatment for Metastatic Colorectal Cancer

Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab.

For questions, please contact 480-398-7671


Lung Cancer Trials:

2nd or 3rd line treatment for Non-Small Cell Lung Cancer (NSCLC) after prior Platinum-Based Chemotherapy

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)
For questions please contact 480-398-7671.

Device study for NSCLC Stage 4 after Platinum Failure

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure (LUNAR).
For questions, please contact 480-398-7671

Lymphoma Trials:

Previously treated Non-Hodgkin’s Lymphoma (Follicular, Small Lymphocytic Leukemia, Marginal Zone, Diffuse Large B-Cell Lymphoma)
For questions please contact 480-398-7671.


Melanoma Trials:

Maintenance Treatment for Patients with Resected Stage IIB, IIC, or III Melanoma

A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence.
For questions, please contact 480-398-7671.


Prostate Cancer Trials:

Metastatic castration-resistant prostate cancer with no prior treatment

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)
For questions please contact 480-398-7671.